This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
ECDC’s annual surveillance reports provide a wealth of epidemiological data to support decision-making at the national level. They are mainly intended for public health professionals and policymakers involved in disease prevention and control programmes.
Lymphogranuloma venereum (LGV) is a systemic sexually transmitted infection (STI) caused by Chlamydia trachomatis serovars L1, L2, or L3. In 2021, 1 124 cases of LGV were reported by 23 EU/EEA Member States.
For 2021, 27 EU/EEA Member States reported 184 542 confirmed cases of chlamydia infection. The crude notification rate was 74 cases per 100 000 population.
In a series of reports released by ECDC, a concerning rise in sexually transmitted infections (STIs) across Europe has been revealed indicating troubling trends and significant public health implications.
Despite good access to effective antibiotics, Streptococcus pneumoniae (pneumococci) is still a major cause of disease and death in both developing and developed countries. Pneumococci are the main cause of bacterial respiratory tract infections, such as pneumonia, middle ear infection, and sinusitis, in all age groups.
Haemophilus influenzae type b (Hib) is an obligate human pathogen and an important cause of invasive bacterial infections in both children and adults, with the highest incidence among young children.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).